Skip to main content

Advertisement

SpringerLink
Log in

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The average survival time for patients with recurrent glioblastoma is between 5 and 9 months. Phase I and II trials have shown a modest survival benefit with combination temozolomide and other chemotherapeutics. We conducted a phase I trial of dose-escalating temozolomide with bevacizumab and the proteasome inhibitor bortezomib for patients with recurrent disease. Three groups of three patients were scheduled to receive daily doses of temozolomide at 25, 50, and 75 mg/m2. Fixed doses of bortezomib and bevacizumab were given at standard intervals. Patients were monitored for dose-limiting toxicities (DLT) to determine the maximum-tolerated dose (MTD) of temozolomide with this regimen. No DLT were seen in the first two groups (25 and 50 mg/m2 temozolomide). One patient in the 75 mg/m2 group experienced a grade 4 elevation of ALT and three more patients were accrued for a total of six patients at that dose level. No other DLT occurred, thus making 75 mg/m2 the MTD. Progression-free survival was 3.27 months for all patients and mean overall survival was 20.75 months. The MTD of temozolomide was 75 mg/m2 in combination with bevacizumab and bortezomib for recurrent glioblastoma. Only one patient experienced a severe (Grade 4) elevation of ALT. This study will provide the framework for further studies to elicit effectiveness and better determine a safety profile for this drug combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Grossman SA, Ye X, Piantadosi S et al (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16(8):2443–2449

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  3. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

    Article  CAS  PubMed  Google Scholar 

  4. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12(2):259–266

    Article  CAS  PubMed  Google Scholar 

  5. Brandes AA, Ermani M, Basso U et al (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12(2):255–257

    Article  CAS  PubMed  Google Scholar 

  6. Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16(5):1117–1121

    CAS  PubMed  Google Scholar 

  7. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357–3361

    Article  CAS  PubMed  Google Scholar 

  8. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Committee ACJG (2014) The role of cytotoxic chemotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):501–555

    Article  CAS  PubMed  Google Scholar 

  10. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131–1138

    Article  CAS  PubMed  Google Scholar 

  11. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    Article  CAS  PubMed  Google Scholar 

  12. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745

    Article  CAS  PubMed  Google Scholar 

  13. Olson JJ, Nayak L, Ormond DR et al (2014) The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):557–599

    Article  CAS  PubMed  Google Scholar 

  14. Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M, Wysocki M (2006) Activity of bortezomib in glioblastoma. Anticancer Res 26(6B):4499–4503

    CAS  PubMed  Google Scholar 

  15. Koschny R, Holland H, Sykora J et al (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13(11):3403–3412

    Article  CAS  PubMed  Google Scholar 

  16. Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS (2013) Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J Neurosurg 119(6):1415–1423

    Article  PubMed  PubMed Central  Google Scholar 

  17. Unterkircher T, Cristofanon S, Vellanki SH et al (2011) Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 17(12):4019–4030

    Article  CAS  PubMed  Google Scholar 

  18. Gong X, Schwartz PH, Linskey ME, Bota DA (2011) Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 76(13):1126–1134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P, Papandreou CN (2013) Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs 31(5):1169–1181

    Article  CAS  PubMed  Google Scholar 

  20. Vlachostergios PJ, Hatzidaki E, Stathakis NE, Koukoulis GK, Papandreou CN (2013) Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cell Mol Neurobiol 33(3):313–318

    Article  CAS  PubMed  Google Scholar 

  21. Vlachostergios PJ, Papandreou CN (2015) Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis. Arch Med Sci 11(2):307–310

    Article  CAS  PubMed  Google Scholar 

  22. Lu S, Chen Z, Yang J et al (2010) The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Int J Lab Hematol 32(1 Pt 1):e123–131

    Article  CAS  PubMed  Google Scholar 

  23. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D (2007) Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Research Communications 361(2):549–554

    Article  CAS  Google Scholar 

  24. Nakamura T, Tanaka K, Matsunobu T et al (2007) The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing’s family tumor cells. International journal of oncology 31(4):803–811

    CAS  PubMed  Google Scholar 

  25. Raizer JJ, Chandler JP, Ferrarese R, Grimm SA (2016) A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neurooncol 129(1):139–146

    Article  CAS  PubMed  Google Scholar 

  26. Olson JJ, Bowers G, Zhang Z (2004) Protease inhibitors in a brain tumor model. In: Adams J (ed) Totowa: Humana Press Inc. pp 161–170

    Google Scholar 

  27. Kubicek GJ, Werner-Wasik M, Machtay M et al (2009) Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74(2):433–439

    Article  CAS  PubMed  Google Scholar 

  28. Phuphanich S, Supko JG, Carson KA et al (2010) Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100(1):95–103

    Article  CAS  PubMed  Google Scholar 

  29. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280

    CAS  PubMed  Google Scholar 

  30. Sarganas G, Orzechowski HD, Klimpel A et al (2012) Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 14(5):541–546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28(12):2051–2057

    Article  CAS  PubMed  Google Scholar 

  32. Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165–172

    Article  CAS  PubMed  Google Scholar 

  33. Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96(2):259–269

    Article  CAS  PubMed  Google Scholar 

  34. Reynes G, Martinez-Sales V, Vila V et al (2016) Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. Anticancer Drugs 27(2):133–137

    Article  CAS  PubMed  Google Scholar 

  35. Reynes G, Balana C, Gallego O, Iglesias L, Perez P, Garcia JL (2014) A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. Anticancer Drugs 25(6):717–722

    CAS  PubMed  Google Scholar 

  36. Clarke JL, Iwamoto FM, Sul J et al (2009) Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27(23):3861–3867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bota ZE DA, Reardon DA, Fu BD, Norfleet J, Desjardins A, Linskey ME, Peters K, Friedman HS, Vredenburgh JJ (2011) Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. ASCO Annual Meeting. J Clin Oncol 29:2011 (suppl; abstr 2056)

    Article  Google Scholar 

  38. Wen P, Macdonald D, Reardon D et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972

    Article  PubMed  Google Scholar 

  39. Friday BB, Anderson SK, Buckner J et al (2012) Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14(2):215–221

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

D.J.M. wrote the manuscript and analyzed the data, E.C.C. performed all chart reviews, collected data, assisted in manuscript creation, A.D.V. and W.L.R. were co-investigators for the clinical trial, J.J.O. served as the Primary Investigator for the clinical trial and oversaw all aspects related to its implementation.

Funding

Funding for trial provided through Genetech, Takeda, and Merck.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Emory University School of Medicine, 1365 Clifton Rd NE, Suite B6200, Atlanta, GA, 30322, USA

    D. Jay McCracken & Jeffrey J. Olson

  2. Emory University School of Medicine, Atlanta, GA, USA

    Emma C. Celano

  3. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

    Alfredo D. Voloschin & William L. Read

Authors
  1. D. Jay McCracken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma C. Celano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfredo D. Voloschin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William L. Read
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey J. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Jay McCracken.

Ethics declarations

Conflicts of interest

None of the authors have any conflicts-of-interest to report with respect to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCracken, D.J., Celano, E.C., Voloschin, A.D. et al. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. J Neurooncol 130, 193–201 (2016). https://doi.org/10.1007/s11060-016-2234-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2234-6

Keywords

Search

Navigation